[Clinical effect of alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura]

Zhongguo Dang Dai Er Ke Za Zhi. 2019 Feb;21(2):168-171. doi: 10.7499/j.issn.1008-8830.2019.02.012.
[Article in Chinese]

Abstract

Objective: To study the clinical effect of alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura.

Methods: Children with abdominal Henoch-Schönlein purpura who needed nutritional support were enrolled and stratified according to age, sex and the severity of disease, and were randomly divided into a control group (n=118) and an enriched nutritional support group (n=107). The control group was given nutritional support without using alanyl-glutamine, while the enriched nutritional support group was given alanyl-glutamine-enriched nutritional support. Intravenous steroids were used according to the severity of disease in both groups. Other therapies were the same in the two groups. The two groups were compared in terms of the length of hospital stay, the rate and duration of use of intravenous steroids, the recurrence rate of symptoms during hospitalization, the rate of total parenteral nutrition (TPN), the rate of weight loss and the rate of fasting for more than 5 days. All patients were followed up for 3 months after discharge to monitor the recurrence of symptoms.

Results: There were no significant differences in the length of hospital stay, the rate of TPN and the rate of fasting for more than 5 days between the two groups (P>0.05). Compared with the enriched nutritional support group, the control group showed significant increases in the rate and duration of use of intravenous steroids, the recurrence rate of symptoms and the rate of weight loss (P<0.05). After the 3-month follow-up, all the children resumed normal diet, and the recurrence rate of digestive symptoms was less than 20% in each group. Abdominal pain was the most common symptom (83.33%, 30/36), followed by vomiting and abdominal distention. No digestive hemorrhage was observed. All the symptoms were relieved after symptomatic treatment. No significant difference was found between the two groups in the recurrence rate of digestive symptoms (P=0.693).

Conclusions: Alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura can reduce the use of intravenous steroids and weight loss, but without impact on the length of hospital stay and post-discharge recurrence.

目的: 了解丙氨酰-谷氨酰胺强化营养支持对于腹型过敏性紫癜患儿的临床有效性。

方法: 将需要营养支持的腹型过敏性紫癜患儿依据年龄、性别、病情进行分层,随机分为对照组(n=118)和强化营养组(n=107)。对照组未使用丙氨酰-谷氨酰胺,强化营养组使用丙氨酰-谷氨酰胺,根据病情给予静脉激素,其余治疗相同。比较两组患儿住院总时间、静脉激素使用率和时间、住院期间症状有无反复、全静脉营养使用率、体重降低发生率、禁食> 5 d比例;并在出院后随访3个月,了解症状有无复发。

结果: 两组住院总时间、全静脉营养使用率、禁食> 5 d比例比较差异无统计学意义(P > 0.05);对照组静脉激素的使用比例和时间、症状反复、体重下降比例均高于强化营养组(P < 0.05)。出院后随访3个月,所有患儿均恢复了正常饮食,两组消化道症状复发率均小于20%,主要以腹痛为主要表现(83.33%,30/36),其次为呕吐和腹胀,无消化道出血表现,予以对症治疗可缓解,两组间消化道症状复发率比较差异无统计学意义(P=0.693)。

结论: 丙氨酰-谷氨酰胺强化营养支持治疗腹型过敏性紫癜患儿能够减少静脉激素的使用,降低体重的下降,但是对住院总时间和出院后复发无影响。

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Child
  • Dipeptides
  • Humans
  • IgA Vasculitis*
  • Parenteral Nutrition, Total
  • Recurrence

Substances

  • Dipeptides
  • alanylglutamine

Grants and funding

成都市卫计委科研课题(2016009);四川省卫计委重点普及推广项目(17PJ278)